CSTL Quote, Financials, Valuation and Earnings

Delcath Systems, Inc. has a net margin of -0.6% compared to Castle Biosciences, Inc.'s net margin of 4.04%. Castle Biosciences, Inc.'s return on equity of -2.71% beat Delcath Systems, Inc.'s return on equity of 1.59%.

Castle Biosciences, Inc. has a consensus price target of $37.25, signalling downside risk potential of -3.6%. On the other hand Delcath Systems, Inc. has an analysts' consensus of $22.31 which suggests that it could grow by 128.07%. Given that Delcath Systems, Inc. has higher upside potential than Castle Biosciences, Inc., analysts believe Delcath Systems, Inc. is more attractive than Castle Biosciences, Inc..

Castle Biosciences, Inc. has a beta of 1.142, which suggesting that the stock is 14.213% more volatile than S&P 500. In comparison Delcath Systems, Inc. has a beta of 0.410, suggesting its less volatile than the S&P 500 by 59.033%.

Castle Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Delcath Systems, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Castle Biosciences, Inc. pays -- of its earnings as a dividend. Delcath Systems, Inc. pays out -- of its earnings as a dividend.

Castle Biosciences, Inc. quarterly revenues are $83M, which are larger than Delcath Systems, Inc. quarterly revenues of $20.6M. Castle Biosciences, Inc.'s net income of -$501K is lower than Delcath Systems, Inc.'s net income of $830K. Notably, Castle Biosciences, Inc.'s price-to-earnings ratio is 30.24x while Delcath Systems, Inc.'s PE ratio is 1,124.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Castle Biosciences, Inc. is 3.30x versus 4.66x for Delcath Systems, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

EXACT Sciences Corp. has a net margin of -0.6% compared to Castle Biosciences, Inc.'s net margin of -2.3%. Castle Biosciences, Inc.'s return on equity of -2.71% beat EXACT Sciences Corp.'s return on equity of -38%.

Castle Biosciences, Inc. has a consensus price target of $37.25, signalling downside risk potential of -3.6%. On the other hand EXACT Sciences Corp. has an analysts' consensus of $103.67 which suggests that it could grow by 2.58%. Given that EXACT Sciences Corp. has higher upside potential than Castle Biosciences, Inc., analysts believe EXACT Sciences Corp. is more attractive than Castle Biosciences, Inc..

Castle Biosciences, Inc. has a beta of 1.142, which suggesting that the stock is 14.213% more volatile than S&P 500. In comparison EXACT Sciences Corp. has a beta of 1.417, suggesting its more volatile than the S&P 500 by 41.664%.

Castle Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. EXACT Sciences Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Castle Biosciences, Inc. pays -- of its earnings as a dividend. EXACT Sciences Corp. pays out -- of its earnings as a dividend.

Castle Biosciences, Inc. quarterly revenues are $83M, which are smaller than EXACT Sciences Corp. quarterly revenues of $850.7M. Castle Biosciences, Inc.'s net income of -$501K is higher than EXACT Sciences Corp.'s net income of -$19.6M. Notably, Castle Biosciences, Inc.'s price-to-earnings ratio is 30.24x while EXACT Sciences Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Castle Biosciences, Inc. is 3.30x versus 6.15x for EXACT Sciences Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Illumina, Inc. has a net margin of -0.6% compared to Castle Biosciences, Inc.'s net margin of 13.85%. Castle Biosciences, Inc.'s return on equity of -2.71% beat Illumina, Inc.'s return on equity of 30.55%.

Castle Biosciences, Inc. has a consensus price target of $37.25, signalling downside risk potential of -3.6%. On the other hand Illumina, Inc. has an analysts' consensus of $121.39 which suggests that it could fall by -5.87%. Given that Illumina, Inc. has more downside risk than Castle Biosciences, Inc., analysts believe Castle Biosciences, Inc. is more attractive than Illumina, Inc..

Castle Biosciences, Inc. has a beta of 1.142, which suggesting that the stock is 14.213% more volatile than S&P 500. In comparison Illumina, Inc. has a beta of 1.438, suggesting its more volatile than the S&P 500 by 43.845%.

Castle Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Illumina, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Castle Biosciences, Inc. pays -- of its earnings as a dividend. Illumina, Inc. pays out -- of its earnings as a dividend.

Castle Biosciences, Inc. quarterly revenues are $83M, which are smaller than Illumina, Inc. quarterly revenues of $1.1B. Castle Biosciences, Inc.'s net income of -$501K is lower than Illumina, Inc.'s net income of $150M. Notably, Castle Biosciences, Inc.'s price-to-earnings ratio is 30.24x while Illumina, Inc.'s PE ratio is 28.89x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Castle Biosciences, Inc. is 3.30x versus 4.74x for Illumina, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Star Operating Cos., Inc. has a net margin of -0.6% compared to Castle Biosciences, Inc.'s net margin of 14.56%. Castle Biosciences, Inc.'s return on equity of -2.71% beat Star Operating Cos., Inc.'s return on equity of -3.67%.

Castle Biosciences, Inc. has a consensus price target of $37.25, signalling downside risk potential of -3.6%. On the other hand Star Operating Cos., Inc. has an analysts' consensus of $12.00 which suggests that it could grow by 13.64%. Given that Star Operating Cos., Inc. has higher upside potential than Castle Biosciences, Inc., analysts believe Star Operating Cos., Inc. is more attractive than Castle Biosciences, Inc..

Castle Biosciences, Inc. has a beta of 1.142, which suggesting that the stock is 14.213% more volatile than S&P 500. In comparison Star Operating Cos., Inc. has a beta of 2.714, suggesting its more volatile than the S&P 500 by 171.399%.

Castle Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Star Operating Cos., Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Castle Biosciences, Inc. pays -- of its earnings as a dividend. Star Operating Cos., Inc. pays out 19.54% of its earnings as a dividend. Star Operating Cos., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Castle Biosciences, Inc. quarterly revenues are $83M, which are larger than Star Operating Cos., Inc. quarterly revenues of $23.7M. Castle Biosciences, Inc.'s net income of -$501K is lower than Star Operating Cos., Inc.'s net income of $3.5M. Notably, Castle Biosciences, Inc.'s price-to-earnings ratio is 30.24x while Star Operating Cos., Inc.'s PE ratio is 0.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Castle Biosciences, Inc. is 3.30x versus 0.50x for Star Operating Cos., Inc.. Usually stocks with elevated PS ratios are considered overvalued.